early breast cancer
Conditions
Interventions
Patients will receive anastrozole 1mg daily for 24 weeks and receive radiotherapy (50Gy / 25 fr) at 13 weeks from the start of anastrozole. Patients will receive surgery at 24 weeks.
Sponsors
Osaka Medical Center for Cancer and Cardiovascular Diseases
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Postmenopausal patients with biopsy-proven invasive breast cancer 2) TNM classification: T2 (3cm and larger)-T4, N0-2, M0 3) ER-positive tumor (10% or more positively staining by immunohistochemistry) 4) PS (ECOG): 0 or 1 5) Normal bone marrow, liver and renal function 6) Patients who have never received any treatment for breast cancer 7) Written informed consent is obtained
Exclusion criteria
Exclusion criteria: 1) past history of any invasive malignancy within the previous 5 years 2) past history of breast cancer or synchronous bilateral breast cancer 3) past history of radiotherapy for ipsilateral breast 4) Suspicious of allergy for radiotherapy 5) Past use of aromatase inhibitors 6) Suspicious of allergy for aromatase inhibitors 7) Patients who had received or are receiving any steroids, estrogens or selective estrogen receptor modulators 8) Any reason the physician believes that the patient is not appropriate to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical response rate | — |
Countries
Japan
Contacts
Public ContactMakoto Ishitobi
Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Breast and Endocrine Surgery
Outcome results
None listed